EXN407 is the first topical SRPK1 inhibitor to demonstrate both safety and signals of biological response as monotherapy for these indications.
Salivary gland abnormalities in primary Sjögren’s become more severe over time, study shows
New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, shows that ultrasound-detected salivary gland abnormalities in primary Sjögren’s become more
November 8, 2023